ACON Company Profile and Key Details

ACON has shown weak momentum, losing -14.63% over the past week and -52.11% over the past quarter, though year-to-date performance is down -16.3%. Short-term trend indicators are bullishly aligned (SMA20 -3.18%, SMA50 -35.41%, SMA200 -58.78%). The stock’s 14-day RSI is 38.32 (weak momentum), while the ATR of 0.28 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -98.83% below its high and over 14.53% above its low. Average 10-day trading volume of 44.44 thousand shares is below the 3-month average of 863.40 thousand, indicating normal recent market interest.

Aclarion, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.08. This means the shares are trading below this model’s fair value.

Aclarion, Inc. (NASDAQ:ACON) closed at $2.68 USD, gaining $0.16 (6.35%) from the previous close of $2.52. The stock is currently mid-range between its 52-week high and low $2.34 and $229.50. With a market capitalization of about $1.56 million, Aclarion, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.44). Key stats such as the average daily volume over the past year has been around 887.40 thousand shares, volume is running light vs its 52-week average. Headquartered in Broomfield, CA, Aclarion, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Brent Ness, the company employs approximately 5 people and listed since April 22, 2022. Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States.

Aclarion, Inc. has 1.05 million shares outstanding. The public float is 671.34 thousand shares, elevated short interest at 16.90% of float. This equals 178.16 thousand shares. The short ratio is 0.08 days. Institutional investors hold 4.66% of the float. Insiders own 0.0%. Neal David K holds 104.68 thousand shares, Bond Ryan has 48.53 thousand shares and Wesemann William has 21.04 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Aclarion, Inc. generated EPS of -$1,602.94 over the past year. Five-year average earnings growth is 40.18%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $23.00 to $22.00. The high target offers 758.21% upside. The low target suggests 720.9% downside. The mean target is $22.50. This offers 739.55% upside. Aclarion, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by -23.7%. The prior quarter beat by 21.68%. Over the last six quarters, Apple has recorded several small beats. These include -21.05% in August 14, 2024.

Aclarion, Inc. trades at a P/E ratio of -0.21, slightly below the S&P 500 average, with a price-to-sales ratio of 23.06 and a price-to-book ratio of 0.12 suggesting the stock is closer to book value. The P/FCF stands at -0.24, also below market averages.

Aclarion, Inc. (NASDAQ:ACON) shares are down -16.3% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Aclarion, Inc. trading at a premium to the broader market with a P/E of -0.21. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $9.88, suggesting 268.66% upside. Our AI forecast model points to short-term weakness (-44.4% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Aclarion, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -44.4%, with price expected at $1.49 by March 10, 2026, within a range of $0.72 to $2.24 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by May 25, 2026, with a range of $0.00 to $44.73. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by February 24, 2027, within a range of $0.00 to $2.02 thousand.